Mega - late reply....
The AIPAC P3 trial is strategic 'postering' IMO
There is no chance Immutep will take this to fruition of OS endpoint or full recruitment without a partner.
It's a nod to BP - do not take the P with a low ball offer (partnership/license/takeover) because we have the wherewithal to go it alone for the foreseeable.
Stretching that 'Competitive tension' Marc eludes to.
AIPAC - imminent OS if data is compelling (very likely IMO) may change everything.
COVID - was never part of our plans. Interesting from a clinical effect efti might have on cytokines but not losing any sleep over lack of recruitment.
That said in future if we are to get involved with these types of left field (very worthy) clinical trials. We should be committed and not just passive suppliers of efti or don't get involved at all.
Mega - late reply....The AIPAC P3 trial is strategic...
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
-0.005(1.64%) |
Mkt cap ! $436.3M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 31.3¢ | 30.0¢ | $960.6K | 3.161M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 188729 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 46153 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |